- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.08. | CERO THERAPEUTICS HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.08. | CERO THERAPEUTICS HOLDINGS, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 31.07. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236 | 126 | GlobeNewswire (Europe) | Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results SOUTH SAN FRANSCISCO, Calif.... ► Artikel lesen | |
| CERO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.07. | CERO THERAPEUTICS HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 21.07. | Cero Therapeutics registers up to 12.5M shares for potential sale under equity agreement with Keystone | 1 | Seeking Alpha | ||
| 21.07. | CERO THERAPEUTICS HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 18.07. | Cero Therapeutics schließt weitere Tranche der Serie-D-Finanzierung ab | 9 | Investing.com Deutsch | ||
| 18.07. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.07. | Cero Therapeutics schließt Aktienkaufvereinbarung über 17,5 Mio. US-Dollar ab | 3 | Investing.com Deutsch | ||
| 08.07. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.06. | CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 | 173 | GlobeNewswire (Europe) | SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) ("CERo" or the "Company"), an immunotherapy company developing the next generation of... ► Artikel lesen | |
| 23.06. | Cero Therapeutics-Aktie auf "Kaufen" hochgestuft dank Ansatz für solide Tumore | 3 | Investing.com Deutsch | ||
| 23.06. | Cero Therapeutics stock rating upgraded to Buy on solid tumor approach | 2 | Investing.com | ||
| 17.06. | CERo Therapeutics stock soars after FDA grants Orphan Drug Designation | 6 | Investing.com | ||
| 17.06. | CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML) | 305 | GlobeNewswire (Europe) | SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the... ► Artikel lesen | |
| 13.06. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.06. | CERo Therapeutics announces 1-for-20 reverse stock split effective June 13 | 3 | Seeking Alpha | ||
| 11.06. | CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split | 219 | GlobeNewswire (Europe) | SOUTH SAN FRANSCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the... ► Artikel lesen |
1 2 3 4 Weiter >>
75 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,215 | +0,11 % | dpa-AFX-Überblick: UNTERNEHMEN vom 29.08.2025 - 15.15 Uhr | ROUNDUP: Gerresheimer bekommt überraschend neuen Finanzchef - Aktie erholt DÜSSELDORF - Der zuletzt schwächelnde Pharmaverpackungshersteller Gerresheimer bekommt überraschend einen neuen Finanzchef.... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,905 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| EVOTEC | 5,702 | -2,70 % | Evotec Aktie: Bringt der "Insiderkauf" die große Kurs-Wende? | Ein großer "Insiderkauf" machte bei der Evotec Aktie in dieser Woche Schlagzeilen. Wer dachte, dass der Aktienkauf des CEO von Evotec im Wert von knapp 0,3 Millionen Euro aber massive Dynamik in die... ► Artikel lesen | |
| VERA THERAPEUTICS | 21,900 | -4,62 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 35,510 | 0,00 % | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 19,760 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 33,175 | 0,00 % | Mineralys Therapeutics closes $287.5 million public offering | ||
| TAYSHA GENE THERAPIES | 3,260 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 37,130 | -2,75 % | Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum | ||
| PRAXIS PRECISION MEDICINES | 46,090 | -1,01 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| IMMUNOME | 9,800 | -4,39 % | Immunome Inc. - 10-Q, Quarterly Report | ||
| PHATHOM PHARMACEUTICALS | 12,000 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| BIONTECH | 89,10 | +3,42 % | BioNtech Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| EDGEWISE THERAPEUTICS | 14,620 | -0,10 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Sept. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,805 | 0,00 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress |
CERO THERAPEUTICS HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 6,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERO THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.